medigraphic.com
Instituto Nacional de Salud Pública

2003, Number S3

<< Back Next >>

salud publica mex 2003; 45 (S3)

Cervical carcinogenesis: The role of co-factors and generation of reactive oxygen species

Giuliano A

Language: English
References: 62
Page: 354-360
PDF size: 89.65 Kb.


ABSTRACT

Several HPV co-factors have been proposed, some more or less consistently associated with cervical dysplasia and cancer risk. More research, using prospective cohort designs, is needed to further describe where in carcinogenesis these factors are working and to assess the biological mechanism of these factors. In addition, further research is needed to define the role of various hormonal contraceptive formulations in promoting cervical carcinogenesis. While many interesting scientific questions remain to be answered, results from the numerous epidemiological studies conducted to date indicate that cervical dysplasia and cancer may be reduced if the oxidant antioxidant ratio is shifted to more of and antioxidant profile. In addition to cervical cancer screening, a reduction in cervical cancer incidence may be accomplished by reducing tobacco use, increasing nutritional status, and utilizing barrier contraception to prevent infection with other sexually acquired infections.


REFERENCES

  1. Parkin DM, Pisani P, Ferlay J. Estimates of the world-wide incidence of 25 major cancers in 1990. Int J Cancer 1999;80:827-841.

  2. American Cancer Society. Cancer Facts and Figures 2001. Available at: http://www.cancer.org.

  3. National Cancer Institute. Surveillance Epidemiology and End Results (SEER). Available at: http://seer.cancer.org.

  4. Mitchell MF, Tortolero-Luna G, Wright T et al. Cervical human papillomavirus infection and intraepithelial neoplasia: A review. J Natl Cancer Inst 1996;21:17-25.

  5. Kurman RJ, Henson DE, Herbst AL et al. Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop. JAMA 1994;272:1866-9.

  6. Morrow CP, Cozen W. Perspective on cervical cancer: Why prevent? J Cell Biochem 1995;23(Suppl):61-70.

  7. Schiffman MH. New epidemiology of human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst 1995;87:1345-1347.

  8. Palefsky JM, Holly EA. Molecular virology and epidemiology of human papillomavirus and cervical cancer. Cancer Epidemiol Biomark Prev 1995;4:415-428.

  9. Koutsky LA, Holmes KH, Critchlow CW, Stevens CE, Paaonen J, Beckman AM et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992;327:1272-1278.

  10. Schlecht NF, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura RA et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 2001;286: 3106-3114.

  11. Ho GY, Burk RD, Kein S, Kadish AS, Chang CJ, Papan P et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995;87:1365-1371.

  12. Cuzick J, Terry G, Ho L, Hollingsworth T, Anderson M. Type-specific human papillomavirus DNA in abnormal smears as a predictor of highgrade cervical intraepithelial neoplasia. Br J Cancer. 1994;69:167-171.

  13. Franco EL. Epidemiology of anogenital warts and cancer. En: Reid R, Lörincz A, ed. Human papillomaviruses I. Obstet Gynecol Clin North Am 1996;23:597-623.

  14. Castle PE, Hillier SL, Rabe LK, Hildesheim A, Herrero R, Bratti MC et al. An association of cervical inflammation with high-grade cervical neoplasia in women infected with oncogenic human papillomavirus (HPV). Cancer Epidemiol Biomark Prev 2001;10:1021-1027.

  15. Sedjo RL, Roe DJ, Abrahamsen M, Harris RB, Craft N, Baldwin S et al. Vitamin A, carotenoids, and risk of persistent oncogenic human papillomavirus infection. Cancer Epidemiol Biomark Prev 2002;11(9):876-884.

  16. Giuliano AR, Gapstur S. Can cervical dysplasia and cancer be prevented with nutrients? Nutr Rev 1998;56:9-16.

  17. Giuliano AR, Papenfuss M, Nour M, Canfield LM, Schneider A, Hatch K. Antioxidant nutrients: Associations with persistent human papillomavirus infection. Cancer Epidemiol Biomark Prev 1997;8:917-923.

  18. Castellsague X, Muñoz N. Co-factors in HPV carcinogenesis: The role of parity, oral contraceptives and tobacco smoking. J Natl Cancer Inst Monograph. 2003;(31):20-28.

  19. Castle PE, Giuliano AR. Genital tract infections, cervical inflammation and antioxidant nutriments-assessing their roles as human papillomavirus cofactors. J Natl Cancer Inst Monograph 2003;(31):29-34.

  20. Potischman N, Brinton LA. Nutrition and cervical dysplasia. Cancer Causes Control 1996;7:113-126.

  21. Sedjo RL, Papenfuss MR, Craft NE, Giuliano AR. Effect of plasma micronutrients on clearance of oncogenic human papillomavirus (HPV) infection (United States). Cancer Causes Control 2003;14(4):319-326.

  22. Giuliano AR. The role of nutrients in the prevention of cervical dysplasia and cancer. Nutrition 2000;16(7-8):570-573.

  23. Giuliano AR, Papenfuss M, Abrahamsen M, Inserra P. Differences in factors associated with oncogenic and non-oncogenic HPV infection at the US-Mexico border. Cancer Epidemiol Biomark Prev 2002;11(9):930-934.

  24. Duarte-Franco E, Robitaille J, Santos M, Miyamura R, Rohan T, Ferenczy A et al. HPV Infection as a predictor of the cervical lesion outcome among women with benign cellular changes on PAP cytology. 19th International Papillomavirus Conference; 2001 September 1-7. Costão do Santinho, Florianópolis, Brazil.

  25. Johnson S. Iron catalyzed oxidative damage, in spite of normal ferritin and transferrin saturation levels and its possible role in Werner’s syndrome, Parkinson’s disease, cancer, gout, rheumatoid arthritis, etc. Med Hypotheses 2000;55:242-244.

  26. Nelson RL. Dietary iron and colorectal cancer risk. Free Radic Biol Med 1992;12:161-168.

  27. Comporti M, Signorini C, Buonocore G, Ciccoli L. Iron release, oxidative stress and erythrocyte ageing. Free Radic Biol Med 2002;32:568-576.

  28. Toyokuni S. Iron-induced carcinogenesis: The role of redox regulation. Free Radic Biol Med 1996;20:553-566.

  29. Welch KD, Davis TZ, Van Eden ME, Aust SD. Deleterious iron-mediated oxidation of biomolecules. Free Radic Biol Med 2002;32:577-583.

  30. Huang X, Dai J, Fournier J, Ali AM, Zhang Q, Frenkel K. Ferrous ion autoxidation and its chelation in iron-loaded human liver HepG2 cells. Free Radic Biol Med 2002;32:84-92.

  31. Breuer W, Epsztejn S, Cabantchik ZI. Dynamics of the cytosolic chelatable iron pool of K562 cells. FEBS Lett 1996;382:304-308.

  32. Miller LL, Miller SC, Torti SV, Tsuji Y, Torti FM. Iron-independent induction of ferritin H chain by tumor necrosis factor. Proc Natl Acad Sci USA 1991;88:4946-4950.

  33. Chau N, Benamghar L, Pham QT, Teculescu D, Rebstock E, Mur JM. Mortality of iron miners in Lorraine (France): Relations between lung function and respiratory symptoms and subsequent mortality. Br J Ind Med 1993;50:1017-1031.

  34. Selby JV, Friedman GD. Epidemiologic evidence of an association between body iron stores and risk of cancer. Int J Cancer 1988;41:677-682.

  35. Stevens RG. Iron and the risk of cancer. Med Oncol Tumor Pharmacother 1990;7:177-181.

  36. Stevens RG, Graubard BI, Micozzi MS, Neriishi K, Blumberg BS. Moderate elevation of body iron level and increased risk of cancer occurrence and death. Int J Cancer 1994;56:364-369.

  37. Stevens RG, Jones DY, Micozzi MS, Taylor PR. Body iron stores and the risk of cancer. N Engl J Med 1988;319:1047-1052.

  38. Wurzelmann JI, Silver A, Schreinemachers DM, Sandler RS, Everson RB. Iron intake and the risk of colorectal cancer. Cancer Epidemiol Biomark Prev 1996;5:503-507.

  39. Onorato JM, Thorpe SR, Baynes JW. Immunohistochemical and ELISA assays for biomarkers of oxidative stress in aging and disease. Ann NY Acad Sci 1998;854:277-290.

  40. Nordberg J, Arner ES. Reactive oxygen species, antioxidants and the mammalian thioredoxin system. Free Radic Biol Med 2001;31:1287-1312.

  41. Palmer HJ, Paulson KE. Reactive oxygen species and antioxidants in signal transduction and gene expression. Nutr Rev 1997;55:353-361.

  42. Beck MA, Shi Q, Morris VC, Levander OA. Rapid genomic evolution of a non-virulent Coxsackievirus B3 in selenium-deficient mice results in selection of identical virulent isolates. Nature Med 1995;1:433-436.

  43. Peterhans E. Oxidants and antioxidants in viral diseases: Disease mechanisms and metabolic regulation. J Nutr 1997;127:962S-965S.

  44. Hennet T, Perhans E, Stocker R. Alterations in antioxidant defenses in lung and liver of mice infected with influenza-A virus. J Gen Virol 1992;73: 39-46.

  45. Oda T, Akaike T, Hamamoto T, Suzuki F, Hirano T, Maeda H. Oxygen radicals in influenza-induced pathogenesis and treatment with pyran polymer-conjugated SOD. Science 1989;244:974-976.

  46. Pace GW, Leaf CD. The role of oxidative stress in HIV disease. Free Radic Biol Med 1995;19:523-528.

  47. Packer L, Suzuki YJ. Vitamin E and alpha-lipoate: Role in antioxidant recycling and activation of the NF-kB transcription factor. Mol Aspects Med 1993;14:229-239.

  48. Cripe TP, Alderborn A, Anderson RD, Parkinen S, Bergman P, Haugen TU et al. Transcriptional activation of the human papillomavirus-16 P97 promoter by an 88-nucleotide enhancer containing distinct cell-dependent and AP-1 responsive modules. New Biol 1990;2:450-463.

  49. Offord EA, Beard P. A member of the activator protein 1 family found in keratinocytes but not in fibroblasts required for transcription from a human papillomavirus type 18 promoter. J Virol 1990;64:4792-4798.

  50. Rosl F, Das BC, Lengert M, Geletneky K, zur Hausen H. Antioxidantinduced changes of the AP-1 transcription complex are paralleled by a selective suppression of human papillomavirus transcription. J Virol 1997;71:362-370.

  51. Fontaine V, van der Meijden E, de Graaf J, ter Schegget J, Struyk L.A functional NF-kappaB binding site in the human papillomavirus type 16 long control region. Virology 1997;20;272:40-9.

  52. O’Byrne KJ, Dalgleish AG. Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer 2001;85:473-483.

  53. Meydani S, Wu D, Santos M, Hayek M. Antioxidants and immune response in aged persons: Overview of present evidence. Am J Clin Nutr 1995;62(Suppl):1462S-1467S.

  54. Anderson R, Theron A. Physiological potential of ascorbate, carotene, and a-tocopherol individually and in combination in the prevention of tissue damage, carcinogenesis, and immune dysfunction mediated by phagocyte-derived reactive oxidants. World Rev Nutr Diet 1998;62:27-5.

  55. Khare S, Tang S-C, Pater M, Pater A. Cofactors with HPV infections and oncogenesis. En: Lacey C ed. Papillomavirus reviews: Current Research on Papillomaviruses. London: Leeds University Press, 1996.

  56. Young, IS and Trimble, ER, Measurement of malondialdehyde in plasma by high performance liquid chromatography with fluorimetric detection. Ann Clin Biochem 1991;28:504-508.

  57. Frenkel K, Khasak D, Karkoszka J, Shupack J, Stiller M. Enhanced antibody titers to an oxidized DNA base in inflammatory and neoplastic diseases. Exp Dermatol 1992;1:242-247.

  58. Frenkel K, Karkoszka J, Kim E, Taioli E. Recognition of oxidized DNA bases by sera of patients with inflammatory diseases. Free Radic Biol Med 1993;14:483-94.

  59. Sasson M, Stiller MJ, Shupack JL, Khasak D, Karkoszka J, Frenkel K. Antibody titers to an oxidized thymidine moiety are altered by systemic pharmacotherapy and ultraviolet B phototherapy. Arch Dermatol Res 1993;285:227-9.

  60. Frenkel K, Karkoszka J, Glassman T, Dubin N, Toniolo P et al. Serum autoantibodies recognizing 5-hydroxymethyl-2'-deoxyuridine, an oxidized DNA base, as biomarkers of cancer risk in women. Cancer Epidemiol Biomark Prev 1998;7:49-57.

  61. Frenkel K, Karkoszka J, Powell J, Berwick M, Mooney LA. Anti-5-hydroxymethyl-2'-deoxyuridine (HMdU) autoantibodies (AAB) as biomarkers of cancer risk: Gender differences. Presented at Proceedings of the American Association for Cancer Research; 2000, San Francisco (CA), USA.

  62. Taioli E, Kinney P, Zhitkovich A, Fulton H, Voitkun V, Cosma G et al. Application of reliability models to studies of biomarker validation. Environ Health Perspect 1994;102:306-309.




2020     |     www.medigraphic.com